Tuesday, December 1, 2020
News

Sanofi, GSK to support COVAX with 200mn doses of Covid-19 vaccine

   SocialTwist Tell-a-Friend    Print this Page   COMMENT

London/Paris | Thursday, 2020 1:45:06 AM IST
Drugmakers Sanofi and GlaxoSmithKline on Wednesday said they plan to make available 200 million doses of their Covid-19 vaccine to the World Health Organisation-led COVAX international initiative which aims to ensure equitable global access to vaccines against the novel coronavirus.

The two companies said that they have signed a pact with Gavi, the legal administrator of the COVAX Facility, for their adjuvanted, recombinant protein-based Covid-19 vaccine.

Both companies intend to contribute to COVAX's ambition to ensure successful Covid-19 vaccines reach those in need, whoever they are and wherever they live, once the appropriate approvals are obtained.

"To address a global health crisis of this magnitude, it takes unique partnerships. The commitment we are announcing today for the COVAX Facility can help us together stand a better chance of bringing the pandemic under control," Thomas Triomphe, Executive Vice President and Global Head of Sanofi Pasteur, said in a statement.

"This moment also reflects our long-term commitment to global health and ensures our Covid-19 vaccines are affordable and accessible to those most at risk, everywhere in the world."

Sanofi and GSK initiated a Phase-1/2 study on September 3 with a total of 440 participants, and anticipate first results in early December 2020, to support the initiation of a pivotal Phase-3 study before the end of the year.

If these data are sufficient for licensure application, it is planned to request regulatory approval from the first half of 2021.

In parallel, the companies are scaling up manufacturing of the antigen and adjuvant respectively.

"Since we started working on the development of Covid-19 vaccines, GSK has pledged to make them available to people around the world," said Roger Connor, President of GSK Vaccines added.

"We are proud to be working with Sanofi to make this adjuvanted recombinant protein-based vaccine available to the countries signed up to the COVAX Facility as soon as possible - this has the potential to be a significant contribution to the global fight against Covid-19."

The COVAX Facility is part of COVAX, a global collaboration of governments, global health organisations, businesses and philanthropic organisations working to accelerate development, production, and equitable access to Covid-19 vaccines.

COVAX is co-led by Gavi, the Coalition for Epidemic Preparedness Innovations (CEPI) and WHO and forms the vaccines pillar of the Access to Covid-19 Tools (ACT) Accelerator.

More than 180 countries and economies recently signed onto the COVAX Facility to get timely and cost-effective access to vaccines to meet the global scale of the Covid-19 pandemic.

--IANS gb/vd

( 426 Words)

2020-10-28-19:48:04 (IANS)

 
  LATEST COMMENTS (0)
POST YOUR COMMENT
Comments Not Available
 
POST YOUR COMMENT
 
 
TRENDING TOPICS
 
 
CITY NEWS
MORE CITIES
 
 
 
MORE HEALTH NEWS
Medical colleges in Odisha to reopen fro...
States, UTs directed to check fire safet...
Recoveries continue to outnumber new Cov...
Washington Guv announces Covid exposure ...
Himachal minister just call away for Cov...
Malaria cases in India drops to 5.6mn in...
More...
 
INDIA WORLD ASIA
TRS leaders Mohammed Mahmood Ali, K Kavi...
Auctioning of Goa mining leases is an op...
PM deviates from programme...
To garner support, Mamata to launch camp...
Shiv Sena MLA, son summoned by ED in mon...
With 31,118 new cases, India's COVID-19 ...
More...    
 
 Top Stories
Biden-Harris name Indian-American a... 
Facebook News arrives in UK as comp... 
Global Covid-19 cases surpass 63mn ... 
Canadian PM expresses concern about... 
COVID-19: Hamilton to miss Sakhir G... 
Pakistani rights group demands just... 
Russia registers 26,402 COVID-19 ca... 
Turkish defence ministry announces ...